165 related articles for article (PubMed ID: 31392827)
1. Net-clinical benefit of extended prophylaxis of venous thromboembolism with betrixaban in medically ill patients aged 80 or more.
Ageno W; Lopes RD; Yee MK; Hernandez A; Hull RD; Goldhaber SZ; Gibson CM; Cohen AT
J Thromb Haemost; 2019 Dec; 17(12):2089-2098. PubMed ID: 31392827
[TBL] [Abstract][Full Text] [Related]
2. Comparison of Fatal or Irreversible Events With Extended-Duration Betrixaban Versus Standard Dose Enoxaparin in Acutely Ill Medical Patients: An APEX Trial Substudy.
Gibson CM; Korjian S; Chi G; Daaboul Y; Jain P; Arbetter D; Goldhaber SZ; Hull R; Hernandez AF; Lopes RD; Gold A; Cohen AT; Harrington RA;
J Am Heart Assoc; 2017 Jul; 6(7):. PubMed ID: 28698258
[TBL] [Abstract][Full Text] [Related]
3. Effect of extended-duration thromboprophylaxis on venous thromboembolism and major bleeding among acutely ill hospitalized medical patients: a bivariate analysis.
Chi G; Goldhaber SZ; Kittelson JM; Turpie AGG; Hernandez AF; Hull RD; Gold A; Curnutte JT; Cohen AT; Harrington RA; Gibson CM
J Thromb Haemost; 2017 Oct; 15(10):1913-1922. PubMed ID: 28762617
[TBL] [Abstract][Full Text] [Related]
4. Extended-Duration Betrixaban Reduces the Risk of Rehospitalization Associated With Venous Thromboembolism Among Acutely Ill Hospitalized Medical Patients: Findings From the APEX Trial (Acute Medically Ill Venous Thromboembolism Prevention With Extended Duration Betrixaban Trial).
Chi G; Yee MK; Amin AN; Goldhaber SZ; Hernandez AF; Hull RD; Cohen AT; Harrington RA; Gibson CM
Circulation; 2018 Jan; 137(1):91-94. PubMed ID: 29279341
[No Abstract] [Full Text] [Related]
5. Extended prophylaxis of venous thromboembolism with betrixaban in acutely ill medical patients with and without cancer: insights from the APEX trial.
Ageno W; Lopes RD; Yee MK; Hernandez A; Hull R; Goldhaber SZ; Gibson CM; Cohen AT
J Thromb Thrombolysis; 2020 Feb; 49(2):214-219. PubMed ID: 31493287
[TBL] [Abstract][Full Text] [Related]
6. The design and rationale for the Acute Medically Ill Venous Thromboembolism Prevention with Extended Duration Betrixaban (APEX) study.
Cohen AT; Harrington R; Goldhaber SZ; Hull R; Gibson CM; Hernandez AF; Kitt MM; Lorenz TJ
Am Heart J; 2014 Mar; 167(3):335-41. PubMed ID: 24576517
[TBL] [Abstract][Full Text] [Related]
7. Extended Thromboprophylaxis with Betrixaban in Acutely Ill Medical Patients.
Cohen AT; Harrington RA; Goldhaber SZ; Hull RD; Wiens BL; Gold A; Hernandez AF; Gibson CM;
N Engl J Med; 2016 Aug; 375(6):534-44. PubMed ID: 27232649
[TBL] [Abstract][Full Text] [Related]
8. Betrixaban: A New Oral Factor Xa Inhibitor for Extended Venous Thromboembolism Prophylaxis in High-Risk Hospitalized Patients.
Garland SG; DeRemer CE; Smith SM; Gums JG
Ann Pharmacother; 2018 Jun; 52(6):554-561. PubMed ID: 29338293
[TBL] [Abstract][Full Text] [Related]
9. The safety and efficacy of full- versus reduced-dose betrixaban in the Acute Medically Ill VTE (Venous Thromboembolism) Prevention With Extended-Duration Betrixaban (APEX) trial.
Gibson CM; Halaby R; Korjian S; Daaboul Y; Arbetter DF; Yee MK; Goldhaber SZ; Hull R; Hernandez AF; Lu SP; Bandman O; Leeds JM; Gold A; Harrington RA; Cohen AT;
Am Heart J; 2017 Mar; 185():93-100. PubMed ID: 28267480
[TBL] [Abstract][Full Text] [Related]
10. Betrixaban for Extended Venous Thromboembolism Prophylaxis in High-Risk Hospitalized Patients: Putting the APEX Results into Practice.
Miller KM; Brenner MJ
Drugs; 2019 Feb; 79(3):291-302. PubMed ID: 30719631
[TBL] [Abstract][Full Text] [Related]
11. Extended-duration betrixaban versus shorter-duration enoxaparin for venous thromboembolism prophylaxis in critically ill medical patients: an APEX trial substudy.
Chi G; Gibson CM; Kalayci A; Cohen AT; Hernandez AF; Hull RD; Kahe F; Jafarizade M; Sharfaei S; Liu Y; Harrington RA; Goldhaber SZ
Intensive Care Med; 2019 Apr; 45(4):477-487. PubMed ID: 30778649
[TBL] [Abstract][Full Text] [Related]
12. Extended-Duration Betrixaban Reduces the Risk of Stroke Versus Standard-Dose Enoxaparin Among Hospitalized Medically Ill Patients: An APEX Trial Substudy (Acute Medically Ill Venous Thromboembolism Prevention With Extended Duration Betrixaban).
Gibson CM; Chi G; Halaby R; Korjian S; Daaboul Y; Jain P; Arbetter D; Goldhaber SZ; Hull R; Hernandez AF; Gold A; Bandman O; Harrington RA; Cohen AT;
Circulation; 2017 Feb; 135(7):648-655. PubMed ID: 27881569
[TBL] [Abstract][Full Text] [Related]
13. Rivaroxaban for thromboprophylaxis among patients recently hospitalized for acute infectious diseases: a subgroup analysis of the MAGELLAN study.
Cohoon KP; De Sanctis Y; Haskell L; McBane RD; Spiro TE
J Thromb Haemost; 2018 Jul; 16(7):1278-1287. PubMed ID: 29753308
[TBL] [Abstract][Full Text] [Related]
14. Extended thromboprophylaxis in the acutely ill medical patient after hospitalization - a paradigm shift in post-discharge thromboprophylaxis.
Mahan CE; Burnett AE; Fletcher ML; Spyropoulos AC
Hosp Pract (1995); 2018 Feb; 46(1):5-15. PubMed ID: 29171776
[TBL] [Abstract][Full Text] [Related]
15. Betrixaban for first-line venous thromboembolism prevention in acute medically ill patients with risk factors for venous thromboembolism.
Nafee T; Gibson CM; Yee MK; Alkhalfan F; Chi G; Travis R; Mir M; Kalayci A; Jafarizade M; Ganti A; Kazmi SH; Ghaffarpasand E; Pitliya A; Datta S; Sharfaei S; Alihashemi M; Elsaiey A; Qamar I; Jahansouz M; Talib U; Kahe F; Habibi S; Abdelwahed M; Tariq F; Kaur M; Younes A; Walia SS; Singh A; Dildar SM; Afzal MK; Kerneis M
Expert Rev Cardiovasc Ther; 2018 Nov; 16(11):845-855. PubMed ID: 30296387
[TBL] [Abstract][Full Text] [Related]
16. Overview of betrixaban and its role in clinical practice.
Lekura J; Kalus JS
Am J Health Syst Pharm; 2018 Aug; 75(15):1095-1102. PubMed ID: 29941506
[TBL] [Abstract][Full Text] [Related]
17. Competing risk analysis in a large cardiovascular clinical trial: An APEX substudy.
Arbetter DF; Jain P; Yee MK; Michalak N; Hernandez AF; Hull RD; Goldhaber SZ; Harrington RA; Gold A; Cohen AT; Gibson CM
Pharm Stat; 2017 Nov; 16(6):445-450. PubMed ID: 28840662
[TBL] [Abstract][Full Text] [Related]
18. Betrixaban (Bevyxxa) for VTE prophylaxis in acute medical illness.
Med Lett Drugs Ther; 2018 Jan; 60(1537):4-5. PubMed ID: 29294463
[No Abstract] [Full Text] [Related]
19. Increased benefit of betrixaban among patients with a history of venous thromboembolism: a post-hoc analysis of the APEX trial.
Yee MK; Nafee T; Daaboul Y; Korjian S; AlKhalfan F; Kerneis M; Wiest C; Goldhaber SZ; Hernandez AF; Hull RD; Cohen AT; Harrington RA; Gibson CM
J Thromb Thrombolysis; 2018 Jan; 45(1):1-8. PubMed ID: 29188425
[TBL] [Abstract][Full Text] [Related]
20. Betrixaban: a direct oral inhibitor of activated factor X for the prophylaxis of venous thromboembolism in patients hospitalized for acute medical illness.
Escolar G; Díaz-Ricart M; Arellano-Rodrigo E
Drugs Today (Barc); 2017 Aug; 53(8):423-434. PubMed ID: 29119147
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]